Chinook Therapeutics Alpha and Beta Analysis
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Chinook Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Chinook Therapeutics over a specified time horizon. Remember, high Chinook Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Chinook Therapeutics' market risk premium analysis include:
Beta 1.45 | Alpha 0.89 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Chinook |
Chinook Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Chinook Therapeutics market risk premium is the additional return an investor will receive from holding Chinook Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Chinook Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Chinook Therapeutics' performance over market.| α | 0.89 | β | 1.45 |
Chinook Therapeutics Fundamentals Vs Peers
Comparing Chinook Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Chinook Therapeutics' direct or indirect competition across all of the common fundamentals between Chinook Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Chinook Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Chinook Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Chinook Therapeutics to competition |
| Fundamentals | Chinook Therapeutics | Peer Average |
| Return On Equity | -0.57 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Operating Margin | (39.98) % | (5.51) % |
| Current Valuation | 2.64 B | 16.62 B |
| Shares Outstanding | 67.05 M | 571.82 M |
| Shares Owned By Insiders | 2.19 % | 10.09 % |
| Shares Owned By Institutions | 96.71 % | 39.21 % |
Chinook Therapeutics Opportunities
Chinook Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Moore Kuehn Encourages CWBR, KDNY, GHL, and EMAN Investors to Contact Law Firm | 07/19/2023 |
2 | SG Americas Securities LLC Surprises the Market with Dramatic ... - Best Stocks | 07/20/2023 |
About Chinook Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Chinook or other delisted stocks. Alpha measures the amount that position in Chinook Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Chinook Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Chinook Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chinook Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Chinook Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Chinook Therapeutics. Please utilize our Beneish M Score to check the likelihood of Chinook Therapeutics' management manipulating its earnings.
| 9th of November 2023 Upcoming Quarterly Report | View | |
| 26th of February 2024 Next Financial Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Chinook Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |